Ozan

Ümraniye, Istanbul

Turkiye, 34764

ozan_ozgen@outlook.com

Experienced clinical research professional with expertise in BE/BA studies, clinical trials, and regulatory compliance. Strong skills in stakeholder management, contract negotiation, and portfolio oversight. Leverages data science and programming to drive innovative solutions in pharmaceutical research.

Currently working as a Clinical Research Specialist at Nobel İlaç, managing preclinical and clinical activities while ensuring strict compliance with R&D timelines and product launches. My work involves overseeing regulatory submissions across 50+ countries and coordinating with CROs across Europe, USA, and India.

I hold an MSc in Medical Biotechnology from Akdeniz University, where I developed machine learning models for predicting anticancer properties of peptides. Currently pursuing a PhD in Gene and Cell Therapy, focusing on advanced therapeutic applications.

My research interests include:

Clinical Development of Advanced Therapeutics
Bioinformatics and Machine Learning in Drug Discovery
Technology Transfer (Preclinical & Clinical)
International Regulatory Guidelines

selected publications

In Silico Investigation of Anticancer Properties of Antimicrobial Peptides

Ahmet Ozan Özgen

2024

Abs Bib

A machine learning model—specifically a random forest using amino acid and dipeptide features—was developed to predict anticancer activity in 10,000 antimicrobial peptides (AMPs). The model showed 79.5% accuracy on its validation set, and 1648 peptides demonstrated favorable anticancer properties. Additional analyses included clustering, physicochemical property predictions, and 3D homology modelling. These findings suggest potential dual effects of AMPs in cancer therapy.
@article{ozgen2024anticancer, title = {In Silico Investigation of Anticancer Properties of Antimicrobial Peptides}, author = {Özgen, Ahmet Ozan}, year = {2024}, publisher = {Council of Higher Education,}, }
Enzymatic Targets for Drug Discovery Against Alzheimer’s Disease

Ahmet Ozan Özgen

In Drug Discovery for Alzheimer’s Disease: Recent Advances, 2023

Abs DOI Bib

Alzheimer’s Disease (AD) is a neurodegenerative disease. The disease itself is progressive and full recovery from it isn’t achievable yet. There are several hypotheses asserted (Cholinergic hypothesis, Amyloid hypothesis etc.) to explain the mechanisms behind the disease. Also, many targets have been identified for possible therapeutics and from these targets, numerous drug candidates have been evaluated in clinical trials. Unfortunately, most of these trials failed due to the enigmatic nature of this disease. Currently, there are 7103 targets associated with Alzheimer’s disease listed in the Open Targets platform where 1240 of them are enzyme-related. In this chapter, enzymatic targets of the AD have been reviewed, and those claimed to have disease modifying effects were selected and presented according to their clinical significance.
@incollection{ozgen2023enzymatic, title = {Enzymatic Targets for Drug Discovery Against Alzheimer's Disease}, author = {Özgen, Ahmet Ozan}, booktitle = {Drug Discovery for Alzheimer's Disease: Recent Advances}, publisher = {Bentham Science,}, year = {2023}, url = {https://doi.org/10.2174/9789815136142123010009}, doi = {10.2174/9789815136142123010009}, }